Collegium Pharmaceutical, Inc. (COLL)

In Q1 2025, Collegium reported strong financial results with a 23% year-over-year revenue increase and Jornay PM prescriptions grew by 24%. The company authorized a $25.0 million accelerated share repurchase program in May 2025 and initiated a stock buyback program authorizing the repurchase of up to $150 million in outstanding shares in July 2025. In August 2025, there were instances of insider selling. As of October 22, 2025, Collegium Pharmaceutical has a "Buy" consensus rating from analysts. As of September 23, 2025, the stock price was $34.90 per share, a decline of 7.65% from the previous year, but increased by 2.89% over the last year.

For Collegium Pharmaceutical's products, particularly Jornay PM, there is a recognized demand seasonality. Script growth for Jornay PM typically slows during the summer months but accelerates during the back-to-school season. The company expects the expanded sales force for Jornay PM to significantly impact prescription growth starting in late 2025, with full momentum anticipated in 2026 and beyond.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and other central nervous system disorders. The company's product portfolio includes Jornay PM for ADHD, Belbuca for severe pain, Xtampza ER for pain management, Nucynta ER and IR for pain management, and Symproic for opioid-induced constipation.

Collegium Pharmaceutical, Inc. is headquartered in Stoughton, Massachusetts, United States. The company's primary market and operations appear to be focused within the United States.

Information directly detailing Collegium Pharmaceutical's brand reputation in the past year is not explicitly available. However, the company's focus on abuse-deterrent formulations for pain management and its growth in the ADHD market suggest a commitment to addressing public health concerns and expanding its market presence.

Collegium Pharmaceutical, Inc. has a mixed ownership structure. Approximately 62.41% of the company's stock is owned by institutional investors. Insiders own about 13.39% of the company's stock. Public companies and individual investors own approximately 24.20% to 24.89% of the stock.